A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

This is a single-arm, open-label, multicenter, dose-escalation, and dose-expansion phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and efficacy of LBL-034 in patients with Relapsed/Refractory Multiple Myeloma (R/R MM).

Trial Details

NCT ID
NCT06049290
Phase
PHASE1 / PHASE2
Sponsor
Nanjing Leads Biolabs Co.,Ltd
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • LBL-034 for Injection
Locations (sample)
  • Wuhu, Anhui, China|31.35259,118.42947
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Xiamen, Fujian, China|24.47979,118.08187

Key Eligibility Criteria

  • Agree to follow the trial treatment regimen and visit schedule, voluntarily enroll in the study, and sign the written informed consent form;
  • Age ≥ 18 years at the time of signing the informed consent;
  • Eastern Cooperative Oncology Group (ECOG) Performance Status Scale≤ 1；
  • Documentation of initial diagnosis of multiple myeloma according to IMWG diagnostic criteria；

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →